Idenix Pharmaceuticals Inc. Reaches New 12-Month High at $5.93 (IDIX)
Idenix Pharmaceuticals (NASDAQ:IDIX)’s share price reached a new 52-week high during trading on Thursday, Stock Ratings Network.com reports. The stock traded as high as $5.93 and last traded at $5.72, with a volume of 429,511 shares traded. The stock had previously closed at $5.75.
Several analysts have recently commented on the stock. Analysts at JMP Securities upgraded shares of Idenix Pharmaceuticals (NASDAQ:IDIX) from an “underperform” rating to a “market perform” rating in a research note to investors on Thursday, August 8th. They now have a $1.50 price target on the stock. Separately, analysts at JPMorgan Chase & Co. downgraded shares of Idenix Pharmaceuticals (NASDAQ:IDIX) from a “hold” rating to an “underperform” rating in a research note to investors on Monday, July 8th. Finally, analysts at Bank of America Corp. reiterated an “underperform” rating on shares of Idenix Pharmaceuticals (NASDAQ:IDIX) in a research note to investors on Friday, June 21st.
Three investment analysts have rated the stock with a sell rating and six have given a hold rating to the company. Idenix Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $3.93.
Idenix Pharmaceuticals has a 1-year low of $3.15 and a 1-year high of $5.90. The stock’s 50-day moving average is $4.67 and its 200-day moving average is $4.18. The company’s market cap is $762.2 million.
Idenix Pharmaceuticals, Inc (NASDAQ:IDIX) is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.